Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?

Executive Summary

More and larger M&A deals could boost public biopharmaceutical companies, so investors will watch closely to see if Pfizer's $14bn Medivation acquisition kicks off a widespread spending spree. Speculation about who'll be bought next is in full swing.

Advertisement

Related Content

Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology
Vertex's VX-661 Has Positive Outlook Despite Futility Finding
Allergan Sees Growth From New Launches, Not Big M&A
Merck, Allergan Suggested As Suitors But Biogen's Attractiveness Under Question
Public Biopharma Financings Plunge In 2016, But Is It A Sign Of Health?
Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations
Sanofi Goes Public With Hostile Medivation Bid
Allergan's Back In The (M&A) Saddle Again Post Pfizer Breakup
It's The End Of Pfizergan, So Pfizer Will Have To Grow It Alone
IPF marketers push for more patients

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097169

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel